Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Safety considerations for working with animal models involving human health hazards.

Carpenter CB.

Animal Model Exp Med. 2018 Jul 28;1(2):91-99. doi: 10.1002/ame2.12019. eCollection 2018 Jun. Review.

2.

Effects of increasing space allowance by removing a pig or gate adjustment on finishing pig growth performance.

Carpenter CB, Holder CJ, Wu F, Woodworth JC, DeRouchey JM, Tokach MD, Goodband RD, Dritz SS.

J Anim Sci. 2018 Jun 29;96(7):2659-2664. doi: 10.1093/jas/sky167.

3.
4.

Excellence in patient outcomes as well as hospital performance on process measures: we can do both.

Stanford JR, Carpenter CB, Detore A.

Qual Manag Health Care. 2013 Jan-Mar;22(1):62-5. doi: 10.1097/QMH.0b013e31827dec7f. No abstract available.

PMID:
23271594
5.

A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients.

Womer KL, Magee CC, Najafian N, Vella JP, Milford EL, Sayegh MH, Carpenter CB.

Clin Transplant. 2008 Nov-Dec;22(6):754-9. doi: 10.1111/j.1399-0012.2008.00871.x. Epub 2008 Jul 18.

PMID:
18647327
6.

Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation.

Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R.

J Am Soc Nephrol. 2007 Apr;18(4):1093-102. Epub 2007 Feb 28.

7.

Transplantation 50 years later--progress, challenges, and promises.

Sayegh MH, Carpenter CB.

N Engl J Med. 2004 Dec 23;351(26):2761-6. No abstract available.

PMID:
15616214
8.

Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.

Tkaczuk J, Yu CL, Baksh S, Milford EL, Carpenter CB, Burakoff SJ, McKay DB.

Am J Transplant. 2002 Jan;2(1):31-40.

9.

Why do we reject grafts?

Carpenter CB.

Heart Dis. 2001 Jul-Aug;3(4):270-5. Review.

PMID:
11975804
10.

Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.

Tran HT, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H JR, Kirkman RL, Milford EL.

J Am Soc Nephrol. 2000 Oct;11(10):1903-9.

11.

Improving the success of organ transplantation.

Carpenter CB.

N Engl J Med. 2000 Mar 2;342(9):647-8. No abstract available.

PMID:
10699165
12.

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG.

Nat Med. 2000 Feb;6(2):207-10.

PMID:
10655111
13.

Transfer of specific unresponsiveness to organ allografts by thymocytes.

Hendry WS, Tilney NL, Baldwin WM 3rd, Graves MJ, Milford E, Strom TB, Carpenter CB.

J Am Soc Nephrol. 1999 Nov;10(11):2454-63. No abstract available.

PMID:
10541307
14.

Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides.

Vella JP, Magee C, Vos L, Womer K, Rennke H, Carpenter CB, Hancock W, Sayegh MH.

Transplantation. 1999 Jun 27;67(12):1523-32.

PMID:
10401758
15.

Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Murphy B, Magee CC, Alexander SI, Waaga AM, Snoeck HW, Vella JP, Carpenter CB, Sayegh MH.

J Clin Invest. 1999 Mar;103(6):859-67.

16.

Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.

Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH.

J Clin Invest. 1998 Jun 1;101(11):2309-18.

17.

Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection.

Waaga AM, Chandraker A, Spadafora-Ferreira M, Iyengar AR, Khoury SJ, Carpenter CB, Sayegh MH.

Transplantation. 1998 Apr 15;65(7):876-83.

PMID:
9565089
18.

Uncertainty in xenotransplantation: individual benefit versus collective risk.

Bach FH, Fishman JA, Daniels N, Proimos J, Anderson B, Carpenter CB, Forrow L, Robson SC, Fineberg HV.

Nat Med. 1998 Feb;4(2):141-4. No abstract available.

PMID:
9461178
19.

HLA class I DNA typing in organ transplantation.

Carpenter CB.

Tissue Antigens. 1997 Oct;50(4):322-5. Review. No abstract available.

PMID:
9349613
20.

Role of indirect allorecognition in experimental late acute rejection.

Vella JP, Vos L, Carpenter CB, Sayegh MH.

Transplantation. 1997 Dec 27;64(12):1823-8.

PMID:
9422426
21.

Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction.

Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, Sayegh MH.

Transplantation. 1997 Sep 27;64(6):795-800.

PMID:
9326400
22.

Tolerance and chronic rejection.

Sayegh MH, Carpenter CB.

Kidney Int Suppl. 1997 Mar;58:S11-4. Review. No abstract available.

PMID:
9067936
23.

Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection.

Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH.

Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12439-44.

24.

T cell recognition of xeno-MHC peptides during concordant xenograft rejection.

Murphy B, Auchincloss H Jr, Carpenter CB, Sayegh MH.

Transplantation. 1996 Apr 27;61(8):1133-7.

PMID:
8610405
25.

Mechanisms of oral tolerance by MHC peptides.

Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB.

Ann N Y Acad Sci. 1996 Feb 13;778:338-45. Review.

PMID:
8610987
26.

Role of indirect allorecognition in allograft rejection.

Sayegh MH, Carpenter CB.

Int Rev Immunol. 1996;13(3):221-9. Review.

PMID:
8782743
27.

Long-term failure of renal transplants: adding insult to injury.

Carpenter CB.

Kidney Int Suppl. 1995 Aug;50:S40-4. Review.

PMID:
8544435
28.

Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo.

Khoury SJ, Gallon L, Chen W, Betres K, Russell ME, Hancock WW, Carpenter CB, Sayegh MH, Weiner HL.

J Exp Med. 1995 Aug 1;182(2):357-66.

29.

CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2.

Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA.

J Exp Med. 1995 May 1;181(5):1869-74.

30.

The thymic way to transplantation tolerance.

Remuzzi G, Perico N, Carpenter CB, Sayegh MH.

J Am Soc Nephrol. 1995 Mar;5(9):1639-46. Review.

32.

Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study.

Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, Abrams J, Ryan D, Kelley VR.

Transplantation. 1995 Feb 15;59(3):352-6.

PMID:
7871564
33.

Inhibition of the alloimmune response with synthetic nonpolymorphic class II MHC peptides.

Murphy B, Akalin E, Watschinger B, Carpenter CB, Sayegh MH.

Transplant Proc. 1995 Feb;27(1):409-10. No abstract available.

PMID:
7879041
34.
35.

Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells.

Brandeis JM, Sayegh MH, Gallon L, Blumberg RS, Carpenter CB.

Gastroenterology. 1994 Nov;107(5):1537-42.

PMID:
7926518
36.

T cell activation in cardiac transplant recipients.

McKay DB, Milford EL, Carpenter CB, Kartashov AI, Schoen FJ, Loh E, Aranki SF, Couper GS, Mudge GH.

Transplantation. 1994 Jul 27;58(2):241-5. No abstract available.

PMID:
8042242
37.

Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy.

Sayegh MH, Perico N, Gallon L, Imberti O, Hancock WW, Remuzzi G, Carpenter CB.

Transplantation. 1994 Jul 27;58(2):125-32.

PMID:
8042230
39.

Mechanisms of T cell recognition of alloantigen. The role of peptides.

Sayegh MH, Watschinger B, Carpenter CB.

Transplantation. 1994 May 15;57(9):1295-302. Review. No abstract available.

PMID:
8184464
41.

Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts.

Sayegh MH, Perico N, Imberti O, Hancock WW, Carpenter CB, Remuzzi G.

Transplantation. 1993 Aug;56(2):461-5.

PMID:
7689263
42.
43.

Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation.

Hancock WW, Sayegh MH, Kwok CA, Weiner HL, Carpenter CB.

Transplantation. 1993 May;55(5):1112-8.

PMID:
8497891
44.

Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat.

Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB.

Transplant Proc. 1993 Feb;25(1 Pt 1):357-8. No abstract available.

PMID:
8438333
45.

In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance.

Araten DJ, Lawton T, Ferrara J, Antin JH, Milford E, Carpenter CB, Maziarz RT.

Transplantation. 1993 Jan;55(1):76-82.

PMID:
8420068
46.

In vivo evidence for the Th1/Th2 paradigm: oral alloantigen-induced modulation of accelerated allograft rejection is associated with dense intragraft IL-4.

Hancock WW, Sayegh MH, Carpenter CB.

Transplant Proc. 1992 Oct;24(5):2313-4. No abstract available.

PMID:
1413074
47.

Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat.

Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7762-6.

48.

Oral immunization with allogeneic splenocytes inhibits development of accelerated but not acute rejection of cardiac grafts: analysis of intragraft effector mechanisms.

Hancock WW, Sayegh MH, Zhang ZJ, Kwok CA, Weiner HL, Carpenter CB.

Transplant Proc. 1992 Feb;24(1):250-1. No abstract available.

PMID:
1539269
49.

Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization by skin allografts by orally administered alloantigen.

Sayegh MH, Zhang ZJ, Hancock WW, Kwok CA, Carpenter CB, Weiner HL.

Transplantation. 1992 Jan;53(1):163-6.

PMID:
1733066
50.

Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts.

Tilney NL, Chang A, Milford EL, Whitley WD, Lazarus JM, Ramos EL, Strom TB, Carpenter CB, Kirkman RL.

Ann Surg. 1991 Jul;214(1):42-9.

Supplemental Content

Loading ...
Support Center